What if I am running a longitudinal study?

Eve Technologies cautions against longitudinal studies where possible. 

As outlined by Millipore’s performance specifications, the inter-assay CV for kits run in different sessions is generally <20%. We only perform continued reverification to ensure graded reactivity over time for our Clinical Diagnostics (LDT) assays, as required by CLIA. However, given the extensive range of biomarkers and assays we offer, it is impractical to apply this level of verification to every assay.

Additionally, factors such as shipping and handling of samples, changes in analytical ancillary reagents (e.g., calibration materials), and variations in analyzer fluidic components (e.g., sheath fluid) can contribute to variability. Different kit lot numbers also introduce variability due to differing standard curves, which can impact the calculated observed concentrations.

Given these factors, when submitting samples at multiple timepoints, inter-assay variability becomes a consideration and your data will be influenced by the inherent variables of a longitudinal study and the limitations of immunoassays.

For these reasons, we recommend waiting until all samples are collected before shipping to us.